Inhaled antibiotics for gram-negative respiratory infections

Clinical Microbiology Reviews

Volumn 29, Issue 3, 2016, Pages 581-632

  Wenzler, Eric ^a   Fraidenburg, Dustin R ^a   Scardina, Tonya ^b   Danziger, Larry H ^a,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; COLISTIN; GENTAMICIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; BRONCHIECTASIS; CHEMICAL ENGINEERING; CLINICAL TRIAL (TOPIC); DRUG FORMULATION; GRAM NEGATIVE INFECTION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INHALER; KIDNEY FUNCTION; LUNG FUNCTION; MEDICAL NEBULIZER; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; DRUG DELIVERY SYSTEM; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIOLOGY; RESPIRATORY TRACT INFECTIONS; VETERINARY;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 84969915305     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00101-15     Document Type: Review

References (345)

1. Dessanges JF. 2001. A history of nebulization. J Aerosol Med 14:65-71. http://dx.doi.org/10.1089/08942680152007918.
2. Aiache J-M. 1990. Aerosol therapy in France. J Aerosol Med 3:85-120. http://dx.doi.org/10.1089/jam.1990.3.85.
3. Tiffeneau R, Brun E. 1947. Sur le diamètre des particules dans les aérosols: titre inconnu. Sem Hop Paris 1947(27):5.
4. Mearns MB, Hunt GH, Rushworth R. 1972. Bacterial flora of respiratory tract in patients with cystic fibrosis, 1950-71. Arch Dis Child 47:902-907. http://dx.doi.org/10.1136/adc.47.256.902.
5. Farber JE, Ross J. 1950. The use of aerosol penicillin and streptomycin in bronchopulmonary infections. Calif Med 73:214-217.
6. Kuhn RJ. 2001. Formulation of aerosolized therapeutics. Chest 120:94S-98S. http://dx.doi.org/10.1378/chest.120.3_suppl.94S.
7. Feeley TW, Du Moulin GC, Hedley-Whyte J, Bushnell LS, Gilbert JP, Feingold DS. 1975. Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med 293:471-475. http://dx.doi.org/10.1056 /NEJM197509042931003.
8. Xu J, Murphy SL, Kochanek KD, Bastian BA. 2016. Deaths: final data for 2013. Natl Vital Stat Rep 64:1-119. http://www.cdc.gov/nchs/data /nvsr/nvsr64/nvsr64_02.pdf. Accessed 1 July 2015.
9. Mandell LA, Wunderink RG. 2015. Pneumonia, chapter 153. In Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J (ed), Harrison’s principles of internal medicine, 19th ed. McGraw-Hill, New York, NY.
10. Rodvold KA, George JM, Yoo L. 2011. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet 50:637-664. http://dx.doi.org/10.2165 /11594090-000000000-00000.
11. Sylvester JT, Shimoda LA, Aaronson PI, Ward JP. 2012. Hypoxic pulmonary vasoconstriction. Physiol Rev 92:367-520. http://dx.doi.org /10.1152/physrev.00041.2010.
12. Densen P, Mandell GL. 1980. Phagocyte strategy vs. microbial tactics. Rev Infect Dis 2:817-838. http://dx.doi.org/10.1093/clinids/2.5.817.
13. Krieg DP, Helmke RJ, German VF, Mangos JA. 1988. Resistance of mucoid Pseudomonas aeruginosa to nonopsonic phagocytosis by alveolar macrophages in vitro. Infect Immun 56:3173-3179.
14. Stiver HG, Zachidniak K, Speert DP. 1988. Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseudomonas aeruginosa. Clin Invest Med 11:247-252.
15. Baldwin DR, Honeybourne D, Wise R. 1992. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother 36:1171-1175. http://dx.doi.org/10.1128/AAC.36.6.1171.
16. Wang F, Daugherty B, Keise LL, Wei Z, Foley JP, Savani RC, Koval M. 2003. Heterogeneity of claudin expression by alveolar epithelial cells.Am J Respir Cell Mol Biol 29:62-70. http://dx.doi.org/10.1165/rcmb.2002-0180OC.
17. Campbell L, Abulrob AN, Kandalaft LE, Plummer S, Hollins AJ, Gibbs A, Gumbleton M. 2003. Constitutive expression of p-glycoprotein in normal lung alveolar epithelium and functionality in primary alveolar epithelial cultures. J Pharmacol Exp Ther 304:441-452. http://dx.doi.org /10.1124/jpet.102.042994.
18. Michot JM, Seral C, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. 2005. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob Agents Chemother 49: 2429-2437. http://dx.doi.org/10.1128/AAC.49.6.2429-2437.2005.
19. Hall MJ, DeFrances CJ, Williams SN, Golosinskiy A, Schwartzman A. 2010. National Hospital Discharge Survey: 2007 summary. Natl Health Stat Rep 2010:1-20, 24.
20. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, Torres A. 2002. Community-acquired pneumonia due to Gramnegative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 162:1849-1858. http://dx.doi.org/10.1001 /archinte.162.16.1849.
21. Quartin AA, Scerpella EG, Puttagunta S, Kett DH. 2013. A comparison of microbiology and demographics among patients with healthcareassociated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study. BMC Infect Dis 13:561. http://dx.doi.org/10.1186/1471-2334-13-561.
22. Jones RN. 2010. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 51(Suppl 1):S81-S87. http://dx.doi.org/10.1086/653053.
23. American Thoracic Society, Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388-416. http://dx.doi.org/10.1164/rccm.200405-644ST.
24. Chastre J, Fagon JY. 2002. Ventilator-associated pneumonia. Am J Respir Crit Care Med 165:867-903. http://dx.doi.org/10.1164/ajrccm.165.7.2105078.
25. Gaynes R, Edwards JR, National Nosocomial Infections Surveillance System. 2005. Overview of nosocomial infections caused by gramnegative bacilli. Clin Infect Dis 41:848-854. http://dx.doi.org/10.1086 /432803.
26. Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F. 2007. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13:560-578. http://dx.doi.org/10.1111/j.1469-0691.2007.01681.x.
27. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S, PneumA Trial Group. 2003. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290:2588-2598. http://dx.doi.org/10.1001/jama.290.19.2588.
28. Infectious Diseases Society of America, Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, Eisenstein BI, Gerding D, Lynfield R, Reller LB, Rex J, Schwartz D, Septimus E, Tenover FC, Gilbert DN. 2011. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 52(Suppl 5):S397-S428. http://dx.doi.org/10.1093/cid/cir153.
29. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/drugresistance/threat-report-2013 /pdf/ar-threats-2013-508.pdf. Accessed 26 January 2015.
30. Hede K. 2014. Antibiotic resistance: an infectious arms race. Nature 509:S2-S3. http://dx.doi.org/10.1038/509S2a.
31. Safdar N, Dezfulian C, Collard HR, Saint S. 2005. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 33:2184-2193. http://dx.doi.org/10.1097/01.CCM.0000181731.53912.D9.
32. Ambrose PG, Bhavnani SM, Ellis-Grosse EJ, Drusano GL. 2010. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! Clin Infect Dis 51(Suppl 1):S103-S110. http://dx.doi.org/10.1086/653057.
33. Hagerman JK, Hancock KE, Klepser ME. 2006. Aerosolised antibiotics: a critical appraisal of their use. Expert Opin Drug Deliv 3:71-86. http: //dx.doi.org/10.1517/17425247.3.1.71.
34. Le J, Ashley ED, Neuhauser MM, Brown J, Gentry C, Klepser ME, Marr AM, Schiller D, Schwiesow JN, Tice S, VandenBussche HL, Wood GC, Society of Infectious Diseases Pharmacists Aerosolized Antimicrobials Task Force. 2010. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 30:562-584. http://dx.doi.org/10.1592/phco.30.6.562.
35. Wood GC. 2011. Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia. Expert Rev Anti Infect Ther 9:993-1000. http://dx.doi.org/10.1586/eri.11.126.
36. Patton JS. 1996. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 19:3-36.
37. Patton JS, Fishburn CS, Weers JG. 2004. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 1:338-344. http://dx.doi.org/10.1513/pats.200409-049TA.
38. Ehrmann S, Roche-Campo F, Sferrazza Papa GF, Isabey D, Brochard L, Apiou-Sbirlea G. 2013. Aerosol therapy during mechanical ventilation: an international survey. Intensive Care Med 39:1048-1056. http: //dx.doi.org/10.1007/s00134-013-2872-5.
39. Klastersky J, Huysmans E, Weerts D, Hensgens C, Daneau D. 1974. Endotracheally administered gentamicin for the prevention of infections of the respiratory tract in patients with tracheostomy: a double-blind study. Chest 65:650-654. http://dx.doi.org/10.1378/chest.65.6.650.
40. Klick JM, du Moulin GC, Hedley-Whyte J, Teres D, Bushnell LS, Feingold DS. 1975. Prevention of gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis. II. Effect on the incidence of pneumonia in seriously ill patients. J Clin Invest 55:514-519.
41. Drobnic ME, Sune P, Montoro JB, Ferrer A, Orriols R. 2005. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 39:39-44.
42. Palmer LB, Smaldone GC, Simon SR, O’Riordan TG, Cuccia A. 1998. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med 26:31-39. http://dx.doi.org/10.1097/00003246-199801000-00013.
43. Wood GC, Boucher BA, Croce MA, Hanes SD, Herring VL, Fabian TC. 2002. Aerosolized ceftazidime for prevention of ventilatorassociated pneumonia and drug effects on the proinflammatory response in critically ill trauma patients. Pharmacotherapy 22:972-982. http://dx.doi.org/10.1592/phco.22.12.972.33596.
44. Dalhoff A. 2014. Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients. Clin Microbiol Rev 27:753-782. http://dx.doi.org/10.1128 /CMR.00022-14.
45. Westerman EM, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG. 2004. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cyst Fibros 3:23-28. http://dx.doi.org/10.1016/j.jcf.2003.12.005.
46. Patton JS, Byron PR. 2007. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 6:67-74. http://dx.doi.org /10.1038/nrd2153.
47. Stone KC, Mercer RR, Gehr P, Stockstill B, Crapo JD. 1992. Allometric relationships of cell numbers and size in the mammalian lung. Am J Respir Cell Mol Biol 6:235-243. http://dx.doi.org/10.1165/ajrcmb/6.2.235.
48. Laube BL, Jashnani R, Dalby RN, Zeitlin PL. 2000. Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate. Chest 118:1069-1076. http://dx.doi.org /10.1378/chest.118.4.1069.
49. Kuhn RJ. 2002. Pharmaceutical considerations in aerosol drug delivery. Pharmacotherapy 22:80S-85S. http://dx.doi.org/10.1592/phco.22.6.80S.33907.
50. Brain JD, Valberg PA. 1979. Deposition of aerosol in the respiratory tract. Am Rev Respir Dis 120:1325-1373.
51. Backman P, Adelmann H, Petersson G, Jones CB. 2014. Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product. Clin Pharmacol Ther 95:509-520. http://dx.doi.org/10.1038/clpt.2014.27.
52. Byron PR. 1986. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 75: 433-438. http://dx.doi.org/10.1002/jps.2600750502.
53. Li X, Vogt FG, Hayes D, Jr, Mansour HM. 2014. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery. Eur J Pharm Sci 52:191-205. http://dx.doi.org/10.1016 /j.ejps.2013.10.016.
54. Haynes A, Nakamura J, Heng C, Heuerding S, Thompson G, Malcolmson RJ. 2010. Aerosol performance of tobramycin inhalation powder. Respir Drug Deliv 3:701-706.
55. Geller DE, Weers J, Heuerding S. 2011. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J Aerosol Med Pulm Drug Deliv 24:175-182. http://dx.doi.org/10.1089 /jamp.2010.0855.
56. Miller DP, Tan T, Nakamura J, Malcolmson R, Tarara T, Weers J. 30 June 2015. Physical characterization of tobramycin inhalation powder. I. Rational design of a stable engineered-particle formulation for delivery to the lungs. Mol Pharm http://dx.doi.org/10.1021/acs.molpharmaceut.5b00147.
57. d’Angelo I, Conte C, La Rotonda MI, Miro A, Quaglia F, Ungaro F. 2014. Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies. Adv Drug Deliv Rev 75:92-111. http://dx.doi.org/10.1016/j.addr.2014.05.008.
58. Mansour HM, Rhee YS, Wu X. 2009. Nanomedicine in pulmonary delivery. Int J Nanomedicine 4:299-319.
59. Moreno-Sastre M, Pastor M, Salomon CJ, Esquisabel A, Pedraz JL. 22 July 2015. Pulmonary drug delivery: a review on nanocarriers for antibacterial chemotherapy. J Antimicrob Chemother http://dx.doi.org/10.1093/jac/dkv192.
60. Zhou QT, Leung SS, Tang P, Parumasivam T, Loh ZH, Chan HK. 2015. Inhaled formulations and pulmonary drug delivery systems for respiratory infections. Adv Drug Deliv Rev 85:83-99. http://dx.doi.org /10.1016/j.addr.2014.10.022.
61. Stockmann C, Roberts JK, Yellepeddi VK, Sherwin CM. 2015. Clinical pharmacokinetics of inhaled antimicrobials. Clin Pharmacokinet 54: 473-492. http://dx.doi.org/10.1007/s40262-015-0250-x.
62. Kelly C, Jefferies C, Cryan SA. 2011. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv 2011:727241. http://dx.doi.org/10.1155/2011/727241.
63. Sackner MA, Hirsch J, Epstein S. 1975. Effect of cuffed endotracheal tubes on tracheal mucous velocity. Chest 68:774-777. http://dx.doi.org /10.1378/chest.68.6.774.
64. Husain S, Capitano B, Corcoran T, Studer SM, Crespo M, Johnson B, Pilewski JM, Shutt K, Pakstis DL, Zhang S, Carey ME, Paterson DL, McCurry KR, Venkataramanan R. 2010. Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients. Transplantation 90: 1215-1219. http://dx.doi.org/10.1097/TP.0b013e3181f995ea.
65. Montgomery AB, Pitlick WH, Nardella P, Tracewell WG, Ramsey BW. 2000. Sputum concentrations and systemic pharmacokinetics of aerosolized tobramycin (Tobi) in diseased lungs. Respir Drug Deliv 1:19-24.
66. Dolovich MB, Dhand R. 2011. Aerosol drug delivery: developments in device design and clinical use. Lancet 377:1032-1045. http://dx.doi.org /10.1016/S0140-6736(10)60926-9.
67. Hickey AJ. 2013. Back to the future: inhaled drug products. J Pharm Sci 102:1165-1172. http://dx.doi.org/10.1002/jps.23465.
68. Patton JS, Brain JD, Davies LA, Fiegel J, Gumbleton M, Kim KJ, Sakagami M, Vanbever R, Ehrhardt C. 2010. The particle has landed-characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv 23(Suppl 2):S71-S87. http://dx.doi.org/10.1089/jamp.2010.0836.
69. Hess D, Fisher D, Williams P, Pooler S, Kacmarek RM. 1996. Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 110:498-505.
70. Coates AL, MacNeish CF, Meisner D, Kelemen S, Thibert R, Mac-Donald J, Vadas E. 1997. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Chest 111:1206-1212. http://dx.doi.org/10.1378/chest.111.5.1206.
71. Vecellio L, Abdelrahim ME, Montharu J, Galle J, Diot P, Dubus JC. 2011. Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin. J Cyst Fibros 10:86-92. http://dx.doi.org/10.1016/j.jcf.2010.10.004.
72. O’Riordan TG. 2002. Formulations and nebulizer performance. Respir Care 47:1305-1312; discussion 1312-1313.
73. Loffert DT, Ikle D, Nelson HS. 1994. A comparison of commercial jet nebulizers. Chest 106:1788-1792. http://dx.doi.org/10.1378/chest.106.6.1788.
74. Waldrep JC, Keyhani K, Black M, Knight V. 1994. Operating characteristics of 18 different continuous-flow jet nebulizers with beclomethasone dipropionate liposome aerosol. Chest 105:106-110. http://dx.doi.org/10.1378/chest.105.1.106.
75. Daniels T, Mills N, Whitaker P. 2013. Nebuliser systems for drug delivery in cystic fibrosis. Cochrane Database Syst Rev 4:CD007639. http: //dx.doi.org/10.1002/14651858.CD007639.pub2.
76. Goode ML, Fink JB, Dhand R, Tobin MJ. 2001. Improvement in aerosol delivery with helium-oxygen mixtures during mechanical ventilation. Am J Respir Crit Care Med 163:109-114. http://dx.doi.org/10.1164/ajrccm.163.1.2003025.
77. Dhand R. 2002. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 47:1406-1416; discussion 1416-1418.
78. Geller DE, Rosenfeld M, Waltz DA, Wilmott RW, AeroDose TOBI Study Group. 2003. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest 123:28-36. http://dx.doi.org/10.1378 /chest.123.1.28.
79. Dhand R. 2008. Aerosol delivery during mechanical ventilation: from basic techniques to new devices. J Aerosol Med Pulm Drug Deliv 21:45-60. http://dx.doi.org/10.1089/jamp.2007.0663.
80. Haddrell AE, Davies JF, Miles RE, Reid JP, Dailey LA, Murnane D. 2014. Dynamics of aerosol size during inhalation: hygroscopic growth of commercial nebulizer formulations. Int J Pharm 463:50-61. http://dx.doi.org/10.1016/j.ijpharm.2013.12.048.
81. Heyder J. 2004. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc 1:315-320. http://dx.doi.org/10.1513/pats.200409-046TA.
82. Mainz JG, Schadlich K, Schien C, Michl R, Schelhorn-Neise P, Koitschev A, Koitschev C, Keller PM, Riethmuller J, Wiedemann B, Beck JF. 2014. Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study. Drug Des Devel Ther 8:209-217. http://dx.doi.org/10.2147 /DDDT.S54064.
83. Kesser KC, Geller DE. 2009. New aerosol delivery devices for cystic fibrosis. Respir Care 54:754-767; discussion 767-768. http://dx.doi.org /10.4187/002013209790983250.
84. Tiddens HA, Bos AC, Mouton JW, Devadason S, Janssens HM. 2014. Inhaled antibiotics: dry or wet? Eur Respir J 44:1308-1318. http://dx.doi.org/10.1183/09031936.00090314.
85. Tiddens H. 2004. Inhaled antibiotics. Pediatr Pulmonol Suppl 26:92-94.
86. Harrison MJ, McCarthy M, Fleming C, Hickey C, Shortt C, Eustace JA, Murphy DM, Plant BJ. 2014. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF). J Cyst Fibros 13: 692-698. http://dx.doi.org/10.1016/j.jcf.2014.04.004.
87. Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi G, He E, Geller DE. 2011. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 10:54-61. http://dx.doi.org/10.1016/j.jcf.2010.10.003.
88. Gibson RL, Retsch-Bogart GZ, Oermann C, Milla C, Pilewski J, Daines C, Ahrens R, Leon K, Cohen M, McNamara S, Callahan TL, Markus R, Burns JL. 2006. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 41:656-665. http://dx.doi.org/10.1002/ppul.20429.
89. Daddario MK, Hagerman JK, Klepser ME. 2010. Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis. Infect Drug Resist 3:123-132. http://dx.doi.org/10.2147/IDR.S7838.
90. Godden DJ, Borland C, Lowry R, Higenbottam TW. 1986. Chemical specificity of coughing in man. Clin Sci (Lond) 70:301-306. http://dx.doi.org/10.1042/cs0700301.
91. Lowry RH, Wood AM, Higenbottam TW. 1988. Effects of pH and osmolarity on aerosol-induced cough in normal volunteers. Clin Sci (Lond) 74:373-376. http://dx.doi.org/10.1042/cs0740373.
92. Eschenbacher WL, Boushey HA, Sheppard D. 1984. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am Rev Respir Dis 129:211-215.
93. Hess DR. 2000. Nebulizers: principles and performance. Respir Care 45:609-622.
94. O’Doherty MJ, Thomas SH, Page CJ, Treacher DF, Nunan TO. 1992. Delivery of a nebulized aerosol to a lung model during mechanical ventilation. Effect of ventilator settings and nebulizer type, position, and volume of fill. Am Rev Respir Dis 146:383-388.
95. O’Riordan TG, Greco MJ, Perry RJ, Smaldone GC. 1992. Nebulizer function during mechanical ventilation. Am Rev Respir Dis 145:1117-1122. http://dx.doi.org/10.1164/ajrccm/145.5.1117.
96. O’Doherty MJ, Thomas SH. 1997. Nebuliser therapy in the intensive care unit. Thorax 52(Suppl 2):S56-S59.
97. Chait R, Craney A, Kishony R. 2007. Antibiotic interactions that select against resistance. Nature 446:668-671. http://dx.doi.org/10.1038 /nature05685.
98. Rahal JJ. 2006. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 43:S95-S99. http://dx.doi.org/10.1086/504486.
99. Klemmer A, Kramer I, Kamin W. 2014. Physicochemical compatibility and stability of nebulizable drug admixtures containing dornase alfa and tobramycin. Pulm Pharmacol Ther 28:53-59. http://dx.doi.org/10.1016 /j.pupt.2013.08.003.
100. Kramer I, Schwabe A, Lichtinghagen R, Kamin W. 2009. Physicochemical compatibility of mixtures of dornase alfa and tobramycin containing nebulizer solutions. Pediatr Pulmonol 44:134-141. http://dx.doi.org/10.1002/ppul.20955.
101. Rubin BK. 2015. Aerosol medications for treatment of mucus clearance disorders. Respir Care 60:825-832. http://dx.doi.org/10.4187/respcare.04087.
102. Adi H, Young PM, Chan HK, Stewart P, Agus H, Traini D. 2008. Cospray dried antibiotics for dry powder lung delivery. J Pharm Sci 97: 3356-3366. http://dx.doi.org/10.1002/jps.21239.
103. Tsifansky MD, Yeo Y, Evgenov OV, Bellas E, Benjamin J, Kohane DS. 2008. Microparticles for inhalational delivery of antipseudomonal antibiotics. AAPS J 10:254-260. http://dx.doi.org/10.1208/s12248-008-9033-8.
104. Lee SH, Teo J, Heng D, Ng WK, Chan HK, Tan RB. 2013. Synergistic combination dry powders for inhaled antimicrobial therapy: formulation, characterization and in vitro evaluation. Eur J Pharm Biopharm 83:275-284. http://dx.doi.org/10.1016/j.ejpb.2012.09.002.
105. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, Bassetti M, Malacarne P, Petrosillo N, Galdieri N, Mocavero P, Corcione A, Viscoli C, Zarrilli R, Gallo C, Utili R. 2013. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 57:349-358. http://dx.doi.org/10.1093/cid/cit253.
106. Zhou QT, Sun SP, Chan JG, Wang P, Barraud N, Rice SA, Wang J, Li J, Chan HK. 2015. Novel inhaled combination powder containing amorphous colistin and crystalline rifapentine with enhanced antimicrobial activities against planktonic cells and biofilm of Pseudomonas aeruginosa for respiratory infections. Mol Pharm 12:2594-2603. http://dx.doi.org/10.1021/mp500586p.
107. Zhou QT, Gengenbach T, Denman JA, Yu HH, Li J, Chan HK. 2014. Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection. AAPS J 16:37-47. http://dx.doi.org/10.1208/s12248-013-9537-8.
108. Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, Moorehead L, Montgomery AB, Geller DE, Phase 2 FTI Study Group. 2012. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection.AmJ Respir Crit Care Med 185:171-178. http://dx.doi.org/10.1164/rccm.201105-0924OC.
109. Antoniu S. 2015. Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis. Expert Rev Anti Infect Ther 13:897-905. http://dx.doi.org/10.1586 /14787210.2015.1041925.
110. Pilcer G, De Bueger V, Traina K, Traore H, Sebti T, Vanderbist F, Amighi K. 2013. Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis. Int J Pharm 451:112-120. http://dx.doi.org/10.1016/j.ijpharm.2013.04.069.
111. Tamaoki J, Takeyama K, Tagaya E, Konno K. 1995. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 39:1688-1690. http://dx.doi.org/10.1128/AAC.39.8.1688.
112. Kawamura-Sato K, Iinuma Y, Hasegawa T, Horii T, Yamashino T, Ohta M. 2000. Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob Agents Chemother 44:2869-2872. http://dx.doi.org/10.1128/AAC.44.10.2869-2872.2000.
113. Nalca Y, Jansch L, Bredenbruch F, Geffers R, Buer J, Haussler S. 2006. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob Agents Chemother 50:1680-1688. http://dx.doi.org/10.1128/AAC.50.5.1680-1688.2006.
114. Wallace SJ, Nation RL, Li J, Boyd BJ. 2013. Physicochemical aspects of the coformulation of colistin and azithromycin using liposomes for combination antibiotic therapies. J Pharm Sci 102:1578-1587. http://dx.doi.org/10.1002/jps.23508.
115. Lee SH, Teo J, Heng D, Zhao Y, Ng WK, Chan HK, Tan RB. 2014. Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy. J Pharm Sci 103:1115-1125. http://dx.doi.org/10.1002/jps.23874.
116. Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, Winzeler B, Bingisser R, Elsaesser H, Drozdov D, Arici B, Urwyler SA, Refardt J, Tarr P, Wirz S, Thomann R, Baumgartner C, Duplain H, Burki D, Zimmerli W, Rodondi N, Mueller B, Christ-Crain M. 2015. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebocontrolled trial. Lancet 385:1511-1518. http://dx.doi.org/10.1016/S0140-6736(14)62447-8.
117. Anonymous. 2015. Global Initiative on Chronic Obstructive Lung Disease diagnosis and management guidelines. http://www.goldcopd.org /uploads/users/files/GOLD_Report_2015.pdf. Accessed 18 January 2016.
118. Berlutti F, Morea C, Battistoni A, Sarli S, Cipriani P, Superti F, Ammendolia MG, Valenti P. 2005. Iron availability influences aggregation, biofilm, adhesion and invasion of Pseudomonas aeruginosa and Burkholderia cenocepacia. Int J Immunopathol Pharmacol 18:661-670.
119. Moreau-Marquis S, Coutermarsh B, Stanton BA. 2015. Combination of hypothiocyanite and lactoferrin (ALX-109) enhances the ability of tobramycin and aztreonam to eliminate Pseudomonas aeruginosa biofilms growing on cystic fibrosis airway epithelial cells. J Antimicrob Chemother 70:160-166. http://dx.doi.org/10.1093/jac/dku357.
120. Lee SH, Teo J, Heng D, Zhao Y, Ng WK, Chan HK, Tan LT, Tan RB. 2015. A novel inhaled multi-pronged attack against respiratory bacteria. Eur J Pharm Sci 70:37-44. http://dx.doi.org/10.1016/j.ejps.2015.01.005.
121. Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. 1996. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 18:246-255. http://dx.doi.org/10.1016/S0149-2918 (96)80005-1.
122. Weber B, Hochhaus G. 2013. A pharmacokinetic simulation tool for inhaled corticosteroids. AAPS J 15:159-171. http://dx.doi.org/10.1208 /s12248-012-9420-z.
123. De Backer JW, Vos WG, Vinchurkar SC, Claes R, Drollmann A, Wulfrank D, Parizel PM, Germonpre P, De Backer W. 2010. Validation of computational fluid dynamics in CT-based airway models with SPECT/CT. Radiology 257:854-862. http://dx.doi.org/10.1148/radiol.10100322.
124. Delvadia RR, Longest PW, Byron PR. 2012. In vitro tests for aerosol deposition. I. Scaling a physical model of the upper airways to predict drug deposition variation in normal humans. J Aerosol Med Pulm Drug Deliv 25:32-40. http://dx.doi.org/10.1089/jamp.2011.0905.
125. Miller DD, Amin MM, Palmer LB, Shah AR, Smaldone GC. 2003. Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am J Respir Crit Care Med 168:1205-1209. http://dx.doi.org /10.1164/rccm.200210-1167OC.
126. Diot P, Morra L, Smaldone GC. 1995. Albuterol delivery in a model of mechanical ventilation. Comparison of metered-dose inhaler and nebulizer efficiency. Am J Respir Crit Care Med 152:1391-1394.
127. Williams L, Fletcher GC, Daniel M, Kinsella J. 1999. A simple in vitro method for the evaluation of an ultrasonic nebulizer for drug delivery to intubated, ventilated patients and the effect of nebulizer and ventilator settings on the uptake of fluid from the nebulizer chamber. Eur J Anaesthesiol 16:479-484. http://dx.doi.org/10.1097 /00003643-199907000-00008.
128. Thomas SH, O’Doherty MJ, Fidler HM, Page CJ, Treacher DF, Nunan TO. 1993. Pulmonary deposition of a nebulised aerosol during mechanical ventilation. Thorax 48:154-159. http://dx.doi.org/10.1136/thx.48.2.154.
129. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. 1985. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 132:761-765.
130. Moore JE, Maeda Y, Goldsmith CE, Rendall JC, Elborn JS. 2010. Direct comparison of in vitro susceptibility of wild-type clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI and BRAMITOB (tobramycin inhalation solutions). J Cyst Fibros 9:237-238. http://dx.doi.org/10.1016/j.jcf.2010.03.005.
131. Montgomery AB, Rhomberg PR, Abuan T, Walters KA, Flamm RK. 2014. Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens. Antimicrob Agents Chemother 58:3714-3719. http://dx.doi.org/10.1128/AAC.02780-13.
132. Montgomery AB, Rhomberg PR, Abuan T, Walters KA, Flamm RK. 2014. Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics. Antimicrob Agents Chemother 58:3708-3713. http://dx.doi.org/10.1128 /AAC.02779-13.
133. MacLeod DL, Barker LM, Sutherland JL, Moss SC, Gurgel JL, Kenney TF, Burns JL, Baker WR. 2009. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 64:829-836. http://dx.doi.org/10.1093/jac/dkp282.
134. Anonymous. 2005. Mesa Espanola de Normalizacion de la Sensibilidad y Resistencia a los Antimicrobianos. Recomendaciones del grupo MENSURA para la seleccion de antimicrobianos en el estudio de la sensibilidad y criterios para la interpretacion del antibiograma. MENSURA, Madrid, Spain.
135. Morosini MI, Garcia-Castillo M, Loza E, Perez-Vazquez M, Baquero F, Canton R. 2005. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips. J Clin Microbiol 43:4480-4485. http://dx.doi.org/10.1128/JCM.43.9.4480-4485.2005.
136. So W, Crandon JL, Hamada Y, Nicolau DP. 10 November 2015. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem. J Antimicrob Chemother http://dx.doi.org/10.1093/jac/dkv370.
137. Gatmaitan BG, Carruthers MM, Lerner AM. 1970. Gentamicin in treatment of primary Gram-negative pneumonias. Am J Med Sci 260: 90-94. http://dx.doi.org/10.1097/00000441-197008000-00003.
138. Pines A, Raafat H, Plucinski K. 1967. Gentamicin and colistin in chronic purulent bronchial infections. Br Med J ii:543-545. http://dx.doi.org/10.1136/bmj.2.5551.543.
139. Panidis D, Markantonis SL, Boutzouka E, Karatzas S, Baltopoulos G. 2005. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 128:545-552. http://dx.doi.org/10.1378/chest.128.2.545.
140. Carcas AJ, Garcia-Satue JL, Zapater P, Frias-Iniesta J. 1999. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin Pharmacol Ther 65:245-250. http://dx.doi.org/10.1016/S0009-9236 (99)70103-7.
141. Li M, Byron PR. 2013. Tobramycin disposition in the rat lung following airway administration. J Pharmacol Exp Ther 347:318-324. http://dx.doi.org/10.1124/jpet.113.207415.
142. Marier JF, Brazier JL, Lavigne J, Ducharme MP. 2003. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J Antimicrob Chemother 52:247-252. http://dx.doi.org/10.1093/jac/dkg317.
143. Beaulac C, Sachetelli S, Lagace J. 1999. Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa. J Drug Target 7:33-41. http://dx.doi.org/10.3109 /10611869909085490.
144. Beaulac C, Clement-Major S, Hawari J, Lagace J. 1996. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob Agents Chemother 40:665-669.
145. Beaulac C, Sachetelli S, Lagace J. 1998. In-vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against gram-negative and gram-positive bacteria. J Antimicrob Chemother 41: 35-41. http://dx.doi.org/10.1093/jac/41.1.35.
146. Stratton CW, Warner RR, Coudron PE, Lilly NA. 1999. Bismuth-mediated disruption of the glycocalyx-cell wall of Helicobacter pylori: ultrastructural evidence for a mechanism of action for bismuth salts. J Antimicrob Chemother 43:659-666. http://dx.doi.org/10.1093/jac/43.5.659.
147. Domenico P, Salo RJ, Novick SG, Schoch PE, Van Horn K, Cunha BA. 1997. Enhancement of bismuth antibacterial activity with lipophilic thiol chelators. Antimicrob Agents Chemother 41:1697-1703.
148. Huang CT, Stewart PS. 1999. Reduction of polysaccharide production in Pseudomonas aeruginosa biofilms by bismuth dimercaprol (BisBAL) treatment. J Antimicrob Chemother 44:601-605. http://dx.doi.org/10.1093/jac/44.5.601.
149. Domenico P, O’Leary R, Cunha BA. 1992. Differential effects of bismuth and salicylate salts on the antibiotic susceptibility of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 11:170-175. http://dx.doi.org/10.1007/BF01967072.
150. Veloira WG, Domenico P, LiPuma JJ, Davis JM, Gurzenda E, Kazzaz JA. 2003. In vitro activity and synergy of bismuth thiols and tobramycin against Burkholderia cepacia complex. J Antimicrob Chemother 52:915-919. http://dx.doi.org/10.1093/jac/dkg471.
151. Wu CL, Domenico P, Hassett DJ, Beveridge TJ, Hauser AR, Kazzaz JA. 2002. Subinhibitory bismuth-thiols reduce virulence of Pseudomonas aeruginosa. Am J Respir Cell Mol Biol 26:731-738. http://dx.doi.org/10.1165/ajrcmb.26.6.2001-00020oc.
152. Alhariri M, Omri A. 2013. Efficacy of liposomal bismuth-ethanedithiolloaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection. Antimicrob Agents Chemother 57:569-578. http://dx.doi.org/10.1128/AAC.01634-12.
153. Hirschl RB, Pranikoff T, Gauger P, Schreiner RJ, Dechert R, Bartlett RH. 1995. Liquid ventilation in adults, children, and full-term neonates. Lancet 346:1201-1202. http://dx.doi.org/10.1016/S0140-6736(95)92903-7.
154. Hirschl RB, Overbeck MC, Parent A, Hernandez R, Schwartz S, Dosanjh A, Johnson K, Bartlett RH. 1994. Liquid ventilation provides uniform distribution of perfluorocarbon in the setting of respiratory failure. Surgery 116:159-167; discussion 167-168.
155. Smith DJ, Gambone LM, Tarara T, Meays DR, Dellamary LA, Woods CM, Weers J. 2001. Liquid dose pulmonary instillation of gentamicin PulmoSpheres formulations: tissue distribution and pharmacokinetics in rabbits. Pharm Res 18:1556-1561. http://dx.doi.org/10.1023/A:1013078330485.
156. Fox WW, Weis CM, Cox C, Farina C, Drott H, Wolfson MR, Shaffer TH. 1997. Pulmonary administration of gentamicin during liquid ventilation in a newborn lamb lung injury model. Pediatrics 100:E5.
157. Zelinka MA, Wolfson MR, Calligaro I, Rubenstein SD, Greenspan JS, Shaffer TH. 1997. A comparison of intratracheal and intravenous administration of gentamicin during liquid ventilation. Eur J Pediatr 156: 401-404. http://dx.doi.org/10.1007/s004310050625.
158. Demaeyer P, Akodad EM, Gravet E, Schietecat P, Van Vooren JP, Drowart A, Yernault JC, Legros FJ. 1993. Disposition of liposomal gentamicin following intrabronchial administration in rabbits. J Microencapsul 10:77-88. http://dx.doi.org/10.3109/02652049309015314.
159. Goldstein I, Wallet F, Nicolas-Robin A, Ferrari F, Marquette CH, Rouby JJ. 2002. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am J Respir Crit Care Med 166:1375-1381. http://dx.doi.org/10.1164/rccm.200204-363OC.
160. Elman M, Goldstein I, Marquette CH, Wallet F, Lenaour G, Rouby JJ, Experimental ICU Study Group. 2002. Influence of lung aeration on pulmonary concentrations of nebulized and intravenous amikacin in ventilated piglets with severe bronchopneumonia. Anesthesiology 97: 199-206. http://dx.doi.org/10.1097/00000542-200207000-00028.
161. Hashimoto S, Wolfe E, Guglielmo B, Shanks R, Sundelof J, Pittet JF, Thomas E, Wiener-Kronish J. 1996. Aerosolization of imipenem/ cilastatin prevents Pseudomonas-induced acute lung injury. J Antimicrob Chemother 38:809-818. http://dx.doi.org/10.1093/jac/38.5.809.
162. Ferrari F, Liu ZH, Lu Q, Becquemin MH, Louchahi K, Aymard G, Marquette CH, Rouby JJ. 2008. Comparison of lung tissue concentrations of nebulized ceftazidime in ventilated piglets: ultrasonic versus vibrating plate nebulizers. Intensive Care Med 34:1718-1723. http://dx.doi.org/10.1007/s00134-008-1126-4.
163. Tonnellier M, Ferrari F, Goldstein I, Sartorius A, Marquette CH, Rouby JJ. 2005. Intravenous versus nebulized ceftazidime in ventilated piglets with and without experimental bronchopneumonia: comparative effects of helium and nitrogen. Anesthesiology 102:995-1000. http://dx.doi.org/10.1097/00000542-200505000-00019.
164. Marchand S, Lauda M, Le Moal G, Gobin P, Couet W, Roblot F. 2013. Pharmacokinetics of daptomycin in a patient with severe renal failure not receiving dialysis. Antimicrob Agents Chemother 57:2898-2899. http: //dx.doi.org/10.1128/AAC.00230-13.
165. Sabet M, Miller CE, Nolan TG, Senekeo-Effenberger K, Dudley MN, Griffith DC. 2009. Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Antimicrob Agents Chemother 53:3923-3928. http://dx.doi.org /10.1128/AAC.00268-09.
166. Kassamali Z, Rotschafer JC, Jones RN, Prince RA, Danziger LH. 2013. Polymyxins: wisdom does not always come with age. Clin Infect Dis 57:877-883. http://dx.doi.org/10.1093/cid/cit367.
167. Nation RL, Li J, Turnidge JD. 2013. The urgent need for clear and accurate information on the polymyxins. Clin Infect Dis 57:1656-1657. http://dx.doi.org/10.1093/cid/cit522.
168. Kassamali Z, Rotschafer JC, Jones RN, Prince RA, Danziger LH. 2013. Reply to Nation et al. Clin Infect Dis 57:1657-1658. (Reply.) http://dx.doi.org/10.1093/cid/cit525.
169. Gales AC, Jones RN, Sader HS. 2011. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 66:2070-2074. http://dx.doi.org/10.1093/jac/dkr239.
170. Yapa SWS, Li J, Porter CJH, Nation RL, Patel K, McIntosh MP. 2013. Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections. Antimicrob Agents Chemother 57:5087-5095. http://dx.doi.org/10.1128/AAC.01127-13.
171. Brain JD, Knudson DE, Sorokin SP, Davis MA. 1976. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ Res 11:13-33. http://dx.doi.org/10.1016/0013-9351(76)90107-9.
172. Gontijo AV, Gregoire N, Lamarche I, Gobin P, Couet W, Marchand S. 2014. Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. Colistin. Antimicrob Agents Chemother 58:3950-3956. http://dx.doi.org/10.1128/AAC.02819-14.
173. Lu Q, Girardi C, Zhang M, Bouhemad B, Louchahi K, Petitjean O, Wallet F, Becquemin MH, Le Naour G, Marquette CH, Rouby JJ. 2010. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med 36:1147-1155. http://dx.doi.org/10.1007/s00134-010-1879-4.
174. Barrowcliffe MP, Jones JG. 1987. Solute permeability of the alveolar capillary barrier. Thorax 42:1-10. http://dx.doi.org/10.1136/thx.42.1.1.
175. Marchand S, Bouchene S, de Monte M, Guilleminault L, Montharu J, Cabrera M, Gregoire N, Gobin P, Diot P, Couet W, Vecellio L. 4 June 2015. Pharmacokinetics of colistin methansulphonate (CMS) and colistin after CMS nebulisation in baboon monkeys. Pharm Res http://dx.doi.org/10.1007/s11095-015-1716-0.
176. Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, Weers JG. 2003. Inhalation of a dry powder tobramycin Pulmo-Sphere formulation in healthy volunteers. Chest 124:360-366. http://dx.doi.org/10.1378/chest.124.1.360.
177. Le Conte P, Potel G, Peltier P, Horeau D, Caillon J, Juvin ME, Kergueris MF, Bugnon D, Baron D. 1993. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis 147:1279-1282. http://dx.doi.org/10.1164/ajrccm/147.5.1279.
178. Baran D, de Vuyst P, Ooms HA. 1990. Concentration of tobramycin given by aerosol in the fluid obtained by bronchoalveolar lavage. Respir Med 84:203-204. http://dx.doi.org/10.1016/S0954-6111(08)80035-2.
179. Burdette SD, Limkemann AJ, Slaughter JB, Beam WB, Markert RJ. 2009. Serum concentrations of aerosolized tobramycin in medical, surgical, and trauma patients. Antimicrob Agents Chemother 53:4568. http: //dx.doi.org/10.1128/AAC.00490-09.
180. Badia JR, Soy D, Adrover M, Ferrer M, Sarasa M, Alarcon A, Codina C, Torres A. 2004. Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. J Antimicrob Chemother 54:508-514. http://dx.doi.org/10.1093/jac/dkh326.
181. Odio W, Van Laer E, Klastersky J. 1975. Concentrations of gentamicin in bronchial secretions after intramuscular and endotracheal administration. J Clin Pharmacol 15:518-524. http://dx.doi.org/10.1002/j.1552-4604.1975.tb01474.x.
182. Al-Amoud AI, Clark BJ, Assi KA, Chrystyn H. 2005. Determination of the bioavailability of gentamicin to the lungs following inhalation from two jet nebulizers. Br J Clin Pharmacol 59:542-545. http://dx.doi.org/10.1111/j.1365-2125.2005.02360.x.
183. Omri A, Beaulac C, Bouhajib M, Montplaisir S, Sharkawi M, Lagace J. 1994. Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 38: 1090-1095. http://dx.doi.org/10.1128/AAC.38.5.1090.
184. Weers J, Metzheiser B, Taylor G, Warren S, Meers P, Perkins WR. 2009. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulm Drug Deliv 22:131-138. http://dx.doi.org/10.1089/jamp.2008.0693.
185. Ehrmann S, Mercier E, Vecellio L, Ternant D, Paintaud G, Dequin PF. 2008. Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects. Intensive Care Med 34:755-762. http: //dx.doi.org/10.1007/s00134-007-0935-1.
186. Luyt CE, Clavel M, Guntupalli K, Johannigman J, Kennedy JI, Wood C, Corkery K, Gribben D, Chastre J. 2009. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care 13:R200. http://dx.doi.org/10.1186/cc8206.
187. Montgomery AB, Vallance S, Abuan T, Tservistas M, Davies A. 2014. A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow inline nebulizer system in mechanically ventilated patients. J Aerosol Med Pulm Drug Deliv 27:441-448. http://dx.doi.org /10.1089/jamp.2013.1100.
188. Stass H, Nagelschmitz J, Willmann S, Delesen H, Gupta A, Baumann S. 2013. Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. Clin Drug Invest 33:419-427. http://dx.doi.org /10.1007/s40261-013-0082-0.
189. Imberti R. 2010. Intravenous colistimethate administration and colistin lung tissue concentrations. Intensive Care Med 36:1795. http://dx.doi.org/10.1007/s00134-010-1960-z. (Reply, 36:1796-1797.)
190. Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, Regazzi M. 2010. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 138:1333-1339. http://dx.doi.org/10.1378/chest.10-0463.
191. Markou N, Fousteri M, Markantonis SL, Boutzouka E, Tsigou E, Baltopoulo G. 2011. Colistin penetration in the alveolar lining fluid of critically ill patients treated with IV colistimethate sodium. Chest 139:232-233. http: //dx.doi.org/10.1378/chest.10-1860. (Reply, 139:233-234.)
192. Athanassa ZE, Markantonis SL, Fousteri MZ, Myrianthefs PM, Boutzouka EG, Tsakris A, Baltopoulos GJ. 2012. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med 38:1779-1786. http://dx.doi.org/10.1007 /s00134-012-2628-7.
193. Dudhani RV, Turnidge JD, Nation RL, Li J. 2010. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 65:1984-1990. http://dx.doi.org/10.1093/jac/dkq226.
194. Westerman EM, de Boer AH, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG. 2007. Dry powder inhalation of colistin sulphomethate in healthy volunteers: a pilot study. Int J Pharm 335:41-45. http://dx.doi.org/10.1016/j.ijpharm.2006.11.021.
195. Le Brun PP, de Boer AH, Mannes GP, de Fraiture DM, Brimicombe RW, Touw DJ, Vinks AA, Frijlink HW, Heijerman HG. 2002. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm 54:25-32. http: //dx.doi.org/10.1016/S0939-6411(02)00044-9.
196. de Boer AH, Le Brun PP, van der Woude HG, Hagedoorn P, Heijerman HG, Frijlink HW. 2002. Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as deagglomeration principle. Eur J Pharm Biopharm 54:17-24. http://dx.doi.org/10.1016/S0939-6411(02)00043-7.
197. Laennec RTH. 1819. On mediate auscultation, or a treatise on the diagnosis of diseases of the lungs and heart. J-A Brosson et J-S Chaudé, Paris, France.
198. McGuinness G, Naidich DP. 2002. CT of airways disease and bronchiectasis. Radiol Clin North Am 40:1-19. http://dx.doi.org/10.1016/S0033-8389(03)00105-2.
199. Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots R. 2012. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007. Chest 142:432-439. http://dx.doi.org/10.1378/chest.11-2209.
200. Cole PJ. 1986. Inflammation: a two-edged sword-the model of bronchiectasis. Eur J Respir Dis Suppl 147:6-15.
201. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, Flower CD, Bilton D, Keogan MT. 2000. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 162:1277-1284. http://dx.doi.org/10.1164/ajrccm.162.4.9906120.
202. Barker AF. 2002. Bronchiectasis. N Engl J Med 346:1383-1393. http://dx.doi.org/10.1056/NEJMra012519.
203. Rubin BK. 2003. Overview of cystic fibrosis and non-CF bronchiectasis. Semin Respir Crit Care Med 24:619-628. http://dx.doi.org/10.1055/s-2004-815658.
204. Tunney MM, Einarsson GG, Wei L, Drain M, Klem ER, Cardwell C, Ennis M, Boucher RC, Wolfgang MC, Elborn JS. 2013. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 187: 1118-1126. http://dx.doi.org/10.1164/rccm.201210-1937OC.
205. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. 2007. Microbiologic follow-up study in adult bronchiectasis. Respir Med 101: 1633-1638. http://dx.doi.org/10.1016/j.rmed.2007.03.009.
206. Chan ED, Iseman MD. 2013. Underlying host risk factors for nontuberculous mycobacterial lung disease. Semin Respir Crit Care Med 34:110-123. http://dx.doi.org/10.1055/s-0033-1333573.
207. Joish VN, Spilsbury-Cantalupo M, Operschall E, Luong B, Boklage S. 2013. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Appl Health Econ Health Policy 11:299-304. http://dx.doi.org/10.1007 /s40258-013-0027-z.
208. Bilton D, Henig N, Morrissey B, Gotfried M. 2006. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 130:1503-1510. http: //dx.doi.org/10.1378/chest.130.5.1503.
209. Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, O’Donnell A, Sahn SA, Smith LJ, Stewart JO, Abuan T, Tully H, Van Dalfsen J, Wells CD, Quan J. 2000. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 162:481-485. http://dx.doi.org/10.1164/ajrccm.162.2.9910086.
210. Scheinberg P, Shore E. 2005. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 127:1420-1426. http://dx.doi.org/10.1378/chest.127.4.1420.
211. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL. 1999. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 340:23-30.
212. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. 2012. Short-and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 186:657-665. http://dx.doi.org/10.1164/rccm.201203-0487OC.
213. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, Roman-Sanchez P, Soriano J. 2007. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 132:1565-1572. http://dx.doi.org/10.1378/chest.07-0490.
214. Davies G, Wells AU, Doffman S, Watanabe S, Wilson R. 2006. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J 28:974-979. http://dx.doi.org/10.1183 /09031936.06.00074605.
215. Olsen AM. 1946. Streptomycin aerosol in the treatment of chronic bronchiectasis; preliminary report. Proc Staff Meet Mayo Clin 21:53.
216. Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis Non-CF Guideline Group. 2010. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 65(Suppl 1):i1-i58. http://dx.doi.org /10.1136/thx.2010.136119.
217. Vendrell M, de Gracia J, Olveira C, Martinez MA, Giron R, Maiz L, Canton R, Coll R, Escribano A, Sole A. 2008. Diagnosis and treatment of bronchiectasis Spanish Society of Pneumology and Thoracic Surgery. Arch Bronconeumol 44:629-640. (In Spanish.) http://dx.doi.org/10.1016/S1579-2129(08)60117-2.
218. Vendrell M, Munoz G, de Gracia J. 2015. Evidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis. Open Respir Med J 9:30-36. http://dx.doi.org/10.2174/1874306401509010030.
219. Orriols R, Roig J, Ferrer J, Sampol G, Rosell A, Ferrer A, Vallano A. 1999. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 93:476-480. http://dx.doi.org/10.1016/S0954-6111(99)90090-2.
220. Murray MP, Govan JR, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, Greening AP, Haslett C, Hill AT. 2011. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 183:491-499. http://dx.doi.org/10.1164/rccm.201005-0756OC.
221. Lin HC, Cheng HF, Wang CH, Liu CY, Yu CT, Kuo HP. 1997. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis.AmJ Respir Crit Care Med 155:2024-2029. http://dx.doi.org/10.1164/ajrccm.155.6.9196111.
222. Wilson R, Welte T, Polverino E, De Soyza A, Greville H, O’Donnell A, Alder J, Reimnitz P, Hampel B. 2013. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 41:1107-1115. http://dx.doi.org/10.1183/09031936.00071312.
223. Serisier DJ, Bilton D, De Soyza A, Thompson PJ, Kolbe J, Greville HW, Cipolla D, Bruinenberg P, Gonda I, ORBIT-2 Investigators. 2013. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 68:812-817. http://dx.doi.org/10.1136 /thoraxjnl-2013-203207.
224. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. 2014. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 189:975-982. http: //dx.doi.org/10.1164/rccm.201312-2208OC.
225. Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, Reznek RH, Wedzicha JA. 2004. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease.Am J Respir Crit Care Med 170:400-407. http://dx.doi.org/10.1164/rccm.200305-648OC.
226. Steinfort DP, Steinfort C. 2007. Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J 37:495-498. http://dx.doi.org/10.1111/j.1445-5994.2007.01404.x.
227. Kelly MG, Murphy S, Elborn JS. 2003. Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. Eur J Intern Med 14:488-492. http://dx.doi.org/10.1016/j.ejim.2003.10.002.
228. Berlana D, Llop JM, Manresa F, Jodar R. 2011. Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis. Pharmacotherapy 31:146-157. http://dx.doi.org/10.1592/phco.31.2.146.
229. Barker AF, O’Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, Boersma WG, De Soyza A, Shao L, Zhang J, Haas L, Lewis SA, Leitzinger S, Montgomery AB, McKevitt MT, Gossage D, Quittner AL, O’Riordan TG. 2014. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2:738-749. http://dx.doi.org/10.1016/S2213-2600(14)70165-1.
230. Brodt AM, Stovold E, Zhang L. 2014. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur Respir J 44: 382-393. http://dx.doi.org/10.1183/09031936.00018414.
231. Yang JW, Fan LC, Lu HW, Miao XY, Mao B, Xu JF. 26 January 2015. Efficacy and safety of long-term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: a meta-analysis. Clin Respir J http://dx.doi.org/10.1111/crj.12278.
232. Evans DJ, Bara AI, Greenstone M. 18 April 2007. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev http://dx.doi.org/10.1002/14651858.CD001392.pub2.
233. Hnin K, Nguyen C, Carson KV, Evans DJ, Greenstone M, Smith BJ. 2015. Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults. Cochrane Database Syst Rev 8:CD001392. http://dx.doi.org/10.1002/14651858.CD001392.pub3.
234. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, Poppelwell L, Salih W, Pesci A, Dupont LJ, Fardon TC, De Soyza A, Hill AT. 2014. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 189: 576-585. http://dx.doi.org/10.1164/rccm.201309-1575OC.
235. Craven DE, Chroneou A, Zias N, Hjalmarson KI. 2009. Ventilatorassociated tracheobronchitis: the impact of targeted antibiotic therapy on patient outcomes. Chest 135:521-528. http://dx.doi.org/10.1378 /chest.08-1617.
236. Craven DE. 2008. Ventilator-associated tracheobronchitis (VAT): questions, answers, and a new paradigm? Crit Care 12:157. http://dx.doi.org /10.1186/cc6912.
237. Craven DE, Hjalmarson KI. 2010. Ventilator-associated tracheobronchitis and pneumonia: thinking outside the box. Clin Infect Dis 51(Suppl 1):S59-S66. http://dx.doi.org/10.1086/653051.
238. Torres A, Valencia M. 2005. Does ventilator-associated tracheobronchitis need antibiotic treatment? Crit Care 9:255-256. http://dx.doi.org /10.1186/cc3535.
239. Fabregas N, Torres A, El-Ebiary M, Ramirez J, Hernandez C, Gonzalez J, de la Bellacasa JP, de Anta J, Rodriguez-Roisin R. 1996. Histopathologic and microbiologic aspects of ventilator-associated pneumonia. Anesthesiology 84:760-771. http://dx.doi.org/10.1097 /00000542-199604000-00002.
240. Rouby JJ, Martin De Lassale E, Poete P, Nicolas MH, Bodin L, Jarlier V, Le Charpentier Y, Grosset J, Viars P. 1992. Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects. Am Rev Respir Dis 146:1059-1066.
241. Gerber J, Smirnov A, Wellmer A, Ragheb J, Prange J, Schutz E, Wettich K, Kalich S, Nau R. 2001. Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob Agents Chemother 45:2169-2172. http://dx.doi.org/10.1128/AAC.45.7.2169-2172.2001.
242. A’Court CH, Garrard CS, Crook D, Bowler I, Conlon C, Peto T, Anderson E. 1993. Microbiological lung surveillance in mechanically ventilated patients, using non-directed bronchial lavage and quantitative culture. Q J Med 86:635-648. http://dx.doi.org/10.1093/qjmed/86.10.635.
243. Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A. 1999. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 14:1015-1022. http://dx.doi.org/10.1183/09031936.99.14510159.
244. Nseir S, Di Pompeo C, Pronnier P, Beague S, Onimus T, Saulnier F, Grandbastien B, Mathieu D, Delvallez-Roussel M, Durocher A. 2002. Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome. Eur Respir J 20:1483-1489. http://dx.doi.org/10.1183/09031936.02.00012902.
245. Palmer LB, Smaldone GC, Chen JJ, Baram D, Duan T, Monteforte M, Varela M, Tempone AK, O’Riordan T, Daroowalla F, Richman P. 2008. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med 36:2008-2013. http://dx.doi.org/10.1097/CCM.0b013e31817c0f9e.
246. Athanassa ZE, Myrianthefs PM, Boutzouka EG, Tsakris A, Baltopoulos GJ. 2011. Monotherapy with inhaled colistin for the treatment of patients with ventilator-associated tracheobronchitis due to polymyxinonly-susceptible Gram-negative bacteria. J Hosp Infect 78:335-336. http: //dx.doi.org/10.1016/j.jhin.2011.04.004.
247. Maskin LP, Setten M, Rodriguez PO, Bonelli I, Attie S, Stryjewski ME, Valentini R. 2015. Inhaled colistimethate sodium in ventilatorassociated tracheobronchitis due to multidrug-resistant Gram-negative bacteria. Int J Antimicrob Agents 45:199-200. http://dx.doi.org/10.1016 /j.ijantimicag.2014.09.010.
248. Hamer DH. 2000. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 162:328-330. http://dx.doi.org/10.1164/ajrccm.162.1.9910071.
249. Falagas ME, Sideri G, Korbila IP, Vouloumanou EK, Papadatos JH, Kafetzis DA. 2010. Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis. Pediatr Pulmonol 45:1135-1140. http://dx.doi.org/10.1002/ppul.21302.
250. Pereira GH, Muller PR, Levin AS. 2007. Salvage treatment of pneumo-nia and initial treatment of tracheobronchitis caused by multidrugresistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis 58:235-240. http://dx.doi.org/10.1016/j.diagmicrobio.2007.01.008.
251. Agrafiotis M, Siempos II, Falagas ME. 2010. Frequency, prevention, outcome and treatment of ventilator-associated tracheobronchitis: systematic review and meta-analysis. Respir Med 104:325-336. http://dx.doi.org/10.1016/j.rmed.2009.09.001.
252. Nseir S, Favory R, Jozefowicz E, Decamps F, Dewavrin F, Brunin G, Di Pompeo C, Mathieu D, Durocher A, VAT Study Group. 2008. Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study. Crit Care 12:R62. http://dx.doi.org/10.1186/cc6890.
253. Bonten MJ, Bergmans DC, Ambergen AW, de Leeuw PW, van der Geest S, Stobberingh EE, Gaillard CA. 1996. Risk factors for pneumonia, and colonization of respiratory tract and stomach in mechanically ventilated ICU patients. Am J Respir Crit Care Med 154:1339-1346. http://dx.doi.org/10.1164/ajrccm.154.5.8912745.
254. Fagon JY, Chastre J, Domart Y, Trouillet JL, Pierre J, Darne C, Gibert C. 1989. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 139:877-884.
255. Kaye KS, Pogue JM. 24 October 2015. Infections caused by resistant Gram-negative bacteria: epidemiology and management. Pharmacotherapy http://dx.doi.org/10.1002/phar.1636.
256. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. 2006. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589-1596. http://dx.doi.org /10.1097/01.CCM.0000217961.75225.E9.
257. Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, Kahlmeter G, Pan A, Petrosillo N, Rodriguez-Bano J, Singh N, Venditti M, Yokoe DS, Cookson B, European Society of Clinical Microbiology. 2014. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 20(Suppl 1):1-55. http://dx.doi.org/10.1111/1469-0691.12427.
258. Ioannidou E, Siempos II, Falagas ME. 2007. Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother 60:1216-1226. http://dx.doi.org/10.1093/jac/dkm385.
259. Falagas ME, Kasiakou SK. 2007. Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis. Infection 35:3-10. http://dx.doi.org/10.1007/s15010-007-6104-1.
260. Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT, Hanisch EW, Klarin B, Koeman M, Krueger WA, Lacherade JC, Lorente L, Memish ZA, Morrow LE, Nardi G, van Nieuwenhoven CA, O’Keefe GE, Nakos G, Scannapieco FA, Seguin P, Staudinger T, Topeli A, Ferrer M, Bonten MJ. 2013. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 13:665-671. http://dx.doi.org/10.1016/S1473-3099(13)70081-1.
261. Bekaert M, Timsit JF, Vansteelandt S, Depuydt P, Vesin A, Garrouste-Orgeas M, Decruyenaere J, Clec’h C, Azoulay E, Benoit D, Outcomerea Study Group. 2011. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med 184:1133-1139. http://dx.doi.org/10.1164/rccm.201105-0867OC.
262. Zampieri FG, Nassar AP, Jr, Gusmao-Flores D, Taniguchi LU, Torres A, Ranzani OT. 2015. Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis. Crit Care 19:150. http://dx.doi.org/10.1186/s13054-015-0868-y.
263. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. 1993. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 94:281-288. http://dx.doi.org/10.1016/0002-9343(93)90060-3.
264. Kollef MH. 1993. Ventilator-associated pneumonia. A multivariate analysis. JAMA 270:1965-1970.
265. Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, Kollef MH, VAP Outcomes Scientific Advisory Group. 2002. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 122:2115-2121. http://dx.doi.org/10.1378/chest.122.6.2115.
266. Restrepo MI, Anzueto A, Arroliga AC, Afessa B, Atkinson MJ, Ho NJ, Schinner R, Bracken RL, Kollef MH. 2010. Economic burden of ventilator-associated pneumonia based on total resource utilization. Infect Control Hosp Epidemiol 31:509-515. http://dx.doi.org/10.1086/651669.
267. Kollef MH, Hamilton CW, Ernst FR. 2012. Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol 33:250-256. http://dx.doi.org/10.1086/664049.
268. Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C. 1998. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157: 531-539. http://dx.doi.org/10.1164/ajrccm.157.2.9705064.
269. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. 2000. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407:762-764. http://dx.doi.org/10.1038/35037627.
270. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322. http: //dx.doi.org/10.1126/science.284.5418.1318.
271. Hoffman LR, D’Argenio DA, MacCoss MJ, Zhang Z, Jones RA, Miller SI. 2005. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 436:1171-1175. http://dx.doi.org/10.1038/nature03912.
272. Adair CG, Gorman SP, Byers LM, Jones DS, Feron B, Crowe M, Webb HC, McCarthy GJ, Milligan KR. 2002. Eradication of endotracheal tube biofilm by nebulised gentamicin. Intensive Care Med 28:426-431. http: //dx.doi.org/10.1007/s00134-002-1223-8.
273. Adair CG, Gorman SP, Feron BM, Byers LM, Jones DS, Goldsmith CE, Moore JE, Kerr JR, Curran MD, Hogg G, Webb CH, McCarthy GJ, Milligan KR. 1999. Implications of endotracheal tube biofilm for ventilator-associated pneumonia. Intensive Care Med 25:1072-1076. http://dx.doi.org/10.1007/s001340051014.
274. Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, Perkins WR. 2008. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 61:859-868. http://dx.doi.org/10.1093/jac/dkn059.
275. Abazov VM, Abbott B, Abolins M, Acharya BS, Adams M, Adams T, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Ancu LS, Aoki M, Arnoud Y, Arov M, Askew A, Asman B, Atramentov O, Avila C, BackusMayes J, Badaud F, Bagby L, Baldin B, Bandurin DV, Banerjee S, Barberis E, Baringer P, Barreto J, Bartlett JF, Bassler U, Beale S, Bean A, Begalli M, Begel M, Belanger-Champagne C, Bellantoni L, Benitez JA, Beri SB, Bernardi G, Bernhard R, Bertram I, Besancon M, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Blazey G, Blessing S, Bloom K, Boehnlein A, et al. 2010. Search for sneutrino production in eμ final states in 5.3 fb-1 of pp collisions at square root s=1.96 TeV. Phys Rev Lett 105:191802. http://dx.doi.org/10.1103/PhysRevLett.105.191802.
276. Falagas ME, Siempos II, Bliziotis IA, Michalopoulos A. 2006. Administration of antibiotics via the respiratory tract for the prevention of ICUacquired pneumonia: a meta-analysis of comparative trials. Crit Care 10:R123. http://dx.doi.org/10.1186/cc5032.
277. Dhand R, Guntur VP. 2008. How best to deliver aerosol medications to mechanically ventilated patients. Clin Chest Med 29:277-296. http://dx.doi.org/10.1016/j.ccm.2008.02.003.
278. Luyt CE, Brechot N, Combes A, Trouillet JL, Chastre J. 2013. Delivering antibiotics to the lungs of patients with ventilator-associated pneumonia: an update. Expert Rev Anti Infect Ther 11:511-521. http://dx.doi.org/10.1586/eri.13.36.
279. Nseir S. 2008. Aerosolized antibiotics for ventilator-associated tracheobronchitis: let’s go with the flow! Crit Care Med 36:2191-2192. http://dx.doi.org/10.1097/CCM.0b013e31817c0a28.
280. Kemming GI, Kreyling W, Habler O, Merkel M, Kleen M, Welte M, Messmer K, Zwissler B. 1996. Aerosol production and aerosol droplet size distribution during mechanical ventilation (IPPV) with a new ultrasonic nebulizer. Eur J Med Res 1:321-327.
281. Harvey CJ, O’Doherty MJ, Page CJ, Thomas SH, Nunan TO, Treacher DF. 1995. Effect of a spacer on pulmonary aerosol deposition from a jet nebuliser during mechanical ventilation. Thorax 50:50-53. http://dx.doi.org/10.1136/thx.50.1.50.
282. Davies JB, Bromilow J. 2011. Bacterial filter obstruction with the use of ultrasonic nebulisation. Anaesthesia 66:394-395. http://dx.doi.org/10.1111/j.1365-2044.2011.06683.x.
283. Ehrmann S, Roche-Campo F, Bodet-Contentin L, Razazi K, Dugernier J, Trenado-Alvarez J, Donzeau A, Vermeulen F, Thevoz D, Papanikolaou M, Edelson A, Leon Yoshido H, Piquilloud L, Lakhal K, Lopes C, Vicent C, Desachy A, Apiou-Sbirlea G, Isabey D, Brochard L, Reva Research Network, AT@ICU Study Group. 24 November 2015. Aerosol therapy in intensive and intermediate care units: prospective observation of 2808 critically ill patients. Intensive Care Med http://dx.doi.org/10.1007/s00134-015-4114-5.
284. Lu Q, Luo R, Bodin L, Yang J, Zahr N, Aubry A, Golmard JL, Rouby JJ, Nebulized Antibiotics Study Group. 2012. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 117:1335-1347. http://dx.doi.org /10.1097/ALN.0b013e31827515de.
285. Kwa AL, Loh C, Low JG, Kurup A, Tam VH. 2005. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 41:754-757. http://dx.doi.org/10.1086/432583.
286. Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A. 2009. Inhaled colistin as monotherapy for multidrugresistant gram (-) nosocomial pneumonia: a case series. Respir Med 103: 707-713. http://dx.doi.org/10.1016/j.rmed.2008.11.018.
287. Falagas ME, Agrafiotis M, Athanassa Z, Siempos II. 2008. Administration of antibiotics via the respiratory tract as monotherapy for pneumonia. Expert Rev Anti Infect Ther 6:447-452. http://dx.doi.org/10.1586 /14787210.6.4.447.
288. Nick JA, Moskowitz SM, Chmiel JF, Forssen AV, Kim SH, Saavedra MT, Saiman L, Taylor-Cousar JL, Nichols DP. 2014. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc 11:342-350. http://dx.doi.org/10.1513/AnnalsATS.201310-352OC.
289. Mohr AM, Sifri ZC, Horng HS, Sadek R, Savetamal A, Hauser CJ, Livingston DH. 2007. Use of aerosolized aminoglycosides in the treatment of Gram-negative ventilator-associated pneumonia. Surg Infect (Larchmt) 8:349-357. http://dx.doi.org/10.1089/sur.2006.041.
290. Arnold HM, Sawyer AM, Kollef MH. 2012. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir Care 57:1226-1233. http://dx.doi.org/10.4187/respcare.01556.
291. Hallal A, Cohn SM, Namias N, Habib F, Baracco G, Manning RJ, Crookes B, Schulman CI. 2007. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg Infect (Larchmt) 8:73-82. http://dx.doi.org/10.1089/sur.2006.051.
292. Niederman MS, Chastre J, Corkery K, Fink JB, Luyt CE, Garcia MS. 2012. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med 38:263-271. http://dx.doi.org/10.1007 /s00134-011-2420-0.
293. Czosnowski QA, Wood GC, Magnotti LJ, Croce MA, Swanson JM, Boucher BA, Fabian TC. 2009. Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia. Pharmacotherapy 29: 1054-1060. http://dx.doi.org/10.1592/phco.29.9.1054.
294. Ghannam DE, Rodriguez GH, Raad II, Safdar A. 2009. Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis 28:253-259. http://dx.doi.org /10.1007/s10096-008-0620-5.
295. Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, Falagas ME. 2008. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 102:407-412. http://dx.doi.org/10.1016/j.rmed.2007.10.011.
296. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V. 2010. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 65:2645-2649. http://dx.doi.org/10.1093/jac/dkq360.
297. Tumbarello M, De Pascale G, Trecarichi EM, De Martino S, Bello G, Maviglia R, Spanu T, Antonelli M. 2013. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Chest 144:1768-1775. http://dx.doi.org/10.1378 /chest.13-1018.
298. Bergen PJ, Bulman ZP, Saju S, Bulitta JB, Landersdorfer C, Forrest A, Li J, Nation RL, Tsuji BT. 2015. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. Pharmacotherapy 35: 34-42. http://dx.doi.org/10.1002/phar.1537.
299. Kalin G, Alp E, Coskun R, Demiraslan H, Gundogan K, Doganay M. 2012. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment? J Infect Chemother 18: 872-877. http://dx.doi.org/10.1007/s10156-012-0430-7.
300. Naesens R, Vlieghe E, Verbrugghe W, Jorens P, Ieven M. 2011. A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa. BMC Infect Dis 11:317. http://dx.doi.org/10.1186/1471-2334-11-317.
301. Lin CC, Liu TC, Kuo CF, Liu CP, Lee CM. 2010. Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan. J Microbiol Immunol Infect 43:323-331. http://dx.doi.org/10.1016/S1684-1182(10)60050-3.
302. Doshi NM, Cook CH, Mount KL, Stawicki SP, Frazee EN, Personett HA, Schramm GE, Arnold HM, Murphy CV. 2013. Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study. BMC Anesthesiol 13:45. http://dx.doi.org/10.1186/1471-2253-13-45.
303. Mastoraki A, Douka E, Kriaras I, Stravopodis G, Manoli H, Geroulanos S. 2008. Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients. Surg Infect (Larchmt) 9:153-160. http://dx.doi.org/10.1089/sur.2007.004.
304. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, Samonis G. 2010. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilatorassociated pneumonia: a matched case-control study. Clin Infect Dis 51:1238-1244. http://dx.doi.org/10.1086/657242.
305. Kwa AL, Falagas ME, Michalopoulos A, Tam VH. 2011. Benefits of aerosolized colistin for ventilator-associated pneumonia: absence of proof versus proof of absence? Clin Infect Dis 52:1278-1279. http://dx.doi.org/10.1093/cid/cir134. (Reply, 52:1279-1280. http://dx.doi.org/10.1093/cid/cir135.)
306. van Leeuwen DHJ. 2011. A closer look at aerosolized colistin. Clin Infect Dis 52:1472-1473. http://dx.doi.org/10.1093/cid/cir248. (Reply, 52:1473-1474.)
307. Linden PK, Paterson DL. 2006. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 43(Suppl 2): S89-S94. http://dx.doi.org/10.1086/504485.
308. Berlana D, Llop JM, Fort E, Badia MB, Jodar R. 2005. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm 62:39-47.
309. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME. 2010. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilatorassociated pneumonia: a comparative cohort study. Clin Microbiol Infect 16:1230-1236. http://dx.doi.org/10.1111/j.1469-0691.2009.03040.x.
310. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. 2005. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 9:R53-R59. http://dx.doi.org/10.1186/cc3020.
311. Zylberberg H, Vargaftig J, Barbieux C, Pertuiset N, Rothschild C, Viard JP. 1996. Prolonged efficiency of secondary prophylaxis with colistin aerosols for respiratory infection due to Pseudomonas aeruginosa in patients infected with human immunodeficiency virus. Clin Infect Dis 23:641-643. http://dx.doi.org/10.1093/clinids/23.3.641.
312. Amin M, Rashad A, Fouad A, Abdel Azeem A. 2013. Re-emerging of colistin for treatment of nosocomial pneumonia due to Gram negative multi-drug resistant pathogens in critically ill patients. Egypt J Chest Dis Tuberc 62:447-451. http://dx.doi.org/10.1016/j.ejcdt.2013.05.012.
313. Bogovic TZ, Baronica R, Tomasevic B, Miric M, Drvar Z, Pavlek M, Bratic V, Peric M, Budimir A, Bosnjak Z, Hrabac P. 2014. Inhalation plus intravenous colistin versus intravenous colistin alone for treatment of ventilator associated pneumonia. Signa Vitae 9:29-33.
314. Liu D, Zhang J, Liu HX, Zhu YG, Qu JM. 19 October 2015. Intravenous combined with aerosolized polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens: a systematic review and meta-analysis. Int J Antimicrob Agents http://dx.doi.org/10.1016/j.ijantimicag.2015.09.011.
315. Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ. 2004. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 54:566-569. http://dx.doi.org/10.1093/jac/dkh369.
316. Stoutenbeek CP, van Saene HK, Miranda DR, Zandstra DF, Langrehr D. 1986. Nosocomial gram-negative pneumonia in critically ill patients. A 3-year experience with a novel therapeutic regimen. Intensive Care Med 12:419-423.
317. Lu Q, Yang J, Liu Z, Gutierrez C, Aymard G, Rouby JJ. 2011. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 184: 106-115. http://dx.doi.org/10.1164/rccm.201011-1894OC.
318. Radhakrishnan M, Jaganath A, Rao GS, Kumari HB. 2008. Nebulized imipenem to control nosocomial pneumonia caused by Pseudomonas aeruginosa. J Crit Care 23:148-150. http://dx.doi.org/10.1016/j.jcrc.2007.10.037.
319. Horianopoulou M, Kanellopoulou M, Paraskevopoulos I, Kyriakidis A, Legakis NJ, Lambropoulos S. 2004. Use of inhaled ampicillinsulbactam against multiresistant Acinetobacter baumannii in bronchial secretions of intensive care unit patients. Clin Microbiol Infect 10:85-86. http://dx.doi.org/10.1111/j.1469-0691.2004.00806.x.
320. Karvouniaris M, Makris D, Zygoulis P, Triantaris A, Xitsas S, Mantzarlis K, Petinaki E, Zakynthinos E. 24 September 2015. Nebulised colistin for ventilator-associated pneumonia prevention. Eur Respir J http://dx.doi.org/10.1183/13993003.02235-2014.
321. Horianopoulou M, Lambropoulos S, Papafragas E, Falagas ME. 2005. Effect of aerosolized colistin on multidrug-resistant Pseudomonas aeruginosa in bronchial secretions of patients without cystic fibrosis. J Chemother 17:536-538. http://dx.doi.org/10.1179/joc.2005.17.5.536.
322. Greenfield S, Teres D, Bushnell LS, Hedley-Whyte J, Feingold DS. 1973. Prevention of gram-negative bacillary pneumonia using aerosol polymyxin as prophylaxis. I. Effect on the colonization pattern of the upper respiratory tract of seriously ill patients. J Clin Invest 52:2935-2940.
323. Rouby JJ, Poete P, Martin de Lassale E, Nicolas MH, Bodin L, Jarlier V, Korinek AM, Viars P. 1994. Prevention of gram negative nosocomial bronchopneumonia by intratracheal colistin in critically ill patients. Histologic and bacteriologic study. Intensive Care Med 20:187-192. http: //dx.doi.org/10.1007/BF01704698.
324. Claridge JA, Edwards NM, Swanson J, Fabian TC, Weinberg JA, Wood C, Croce MA. 2007. Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study. Surg Infect (Larchmt) 8:83-90. http: //dx.doi.org/10.1089/sur.2006.042.
325. Wolff RK, Dorato MA. 1993. Toxicologic testing of inhaled pharmaceutical aerosols. Crit Rev Toxicol 23:343-369. http://dx.doi.org/10.3109 /10408449309104076.
326. Rubin BK. 2008. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv 21:71-76. http://dx.doi.org/10.1089/jamp.2007.0652.
327. Canton R, Morosini MI. 2011. Emergence and spread of antibiotic resistance following exposure to antibiotics. FEMS Microbiol Rev 35: 977-991. http://dx.doi.org/10.1111/j.1574-6976.2011.00295.x.
328. Palmer LB, Smaldone GC. 2014. Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. Am J Respir Crit Care Med 189:1225-1233. http://dx.doi.org/10.1164/rccm.201312-2161OC.
329. Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL. 1999. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 179: 1190-1196. http://dx.doi.org/10.1086/314727.
330. Sexauer WP, Fiel SB. 2003. Aerosolized antibiotics in cystic fibrosis. Semin Respir Crit Care Med 24:717-726. http://dx.doi.org/10.1055/s-2004-815667.
331. Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, McKevitt M, Montgomery AB. 2011. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). J Antimicrob Chemother 66:2398-2404. http://dx.doi.org/10.1093/jac/dkr303.
332. Brown RB, Phillips D, Barker MJ, Pieczarka R, Sands M, Teres D. 1989. Outbreak of nosocomial Flavobacterium meningosepticum respiratory infections associated with use of aerosolized polymyxin B. Am J Infect Control 17:121-125.
333. Tsai RJ, Boiano JM, Steege AL, Sweeney MH. 2015. Precautionary practices of respiratory therapists and other health-care practitioners who administer aerosolized medications. Respir Care 60:1409-1417. http://dx.doi.org/10.4187/respcare.03817.
334. Beaty CD, Ritz RH, Benson MS. 1989. Continuous in-line nebulizers complicate pressure support ventilation. Chest 96:1360-1363. http://dx.doi.org/10.1378/chest.96.6.1360.
335. Craven DE, Lichtenberg DA, Goularte TA, Make BJ, McCabe WR. 1984. Contaminated medication nebulizers in mechanical ventilator circuits. Source of bacterial aerosols. Am J Med 77:834-838.
336. McCoy KS. 2007. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. N Engl J Med 357:2310-2311. http: //dx.doi.org/10.1056/NEJMc071717.
337. Hakeam HA, Almohaizeie AM. 2006. Hypotension following treatment with aerosolized colistin in a patient with multidrug-resistant Pseudomonas aeruginosa. Ann Pharmacother 40:1677-1680. http://dx.doi.org/10.1345/aph.1H019.
338. Alothman GA, Alsaadi MM, Ho BL, Ho SL, Dupuis A, Corey M, Coates AL. 2002. Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest 122:930-934. http://dx.doi.org/10.1378/chest.122.3.930.
339. Cunningham S, Prasad A, Collyer L, Carr S, Lynn IB, Wallis C. 2001. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child 84:432-433. http://dx.doi.org/10.1136/adc.84.5.432.
340. Wilson FE. 1981. Acute respiratory failure secondary to polymyxin-B inhalation. Chest 79:237-239. http://dx.doi.org/10.1378/chest.79.2.237.
341. Marschke G, Sarauw A. 1971. Polymyxin inhalation therapeutic hazard. Ann Intern Med 74:144-145. http://dx.doi.org/10.7326/0003-4819-74-1-144.
342. Falagas ME, Kasiakou SK. 2006. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 10:R27. http://dx.doi.org/10.1186/cc3995.
343. Kostyanev T, Bonten MJ, O’Brien S, Steel H, Ross S, Francois B, Tacconelli E, Winterhalter M, Stavenger RA, Karlen A, Harbarth S, Hackett J, Jafri HS, Vuong C, MacGowan A, Witschi A, Angyalosi G, Elborn JS, deWinter R, Goossens H. 15 November 2015. The Innovative Medicines Initiative’s New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. J Antimicrob Chemother http://dx.doi.org /10.1093/jac/dkv339.
344. Kostyanev T, Bonten MJ, O’Brien S, Goossens H. 2015. Innovative Medicines Initiative and antibiotic resistance. Lancet Infect Dis 15:1373-1375. http://dx.doi.org/10.1016/S1473-3099(15)00407-7.
345. Zarogoulidis P, Kioumis I, Ritzoulis C, Petridis D, Darwiche K, Porpodis K, Spyratos D, Parrish S, Browning R, Li Q, Turner JF, Freitag L, Zarogoulidis K. 2013. New insights in the production of aerosol antibiotics. Evaluation of the optimal aerosol production system for ampicillin-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam. Int J Pharm 455:182-188. http://dx.doi.org/10.1016/j.ijpharm.2013.07.040.